Science for Life Laboratory Joins the Illumina Genome Network

  Science for Life Laboratory Joins the Illumina Genome Network

First European Genome Network Partner Plans Large Scale Population Sequencing

Business Wire

SAN DIEGO -- February 24, 2014

Illumina, Inc. (NASDAQ:ILMN) today announced that Science for Life Laboratory
(SciLifeLab) in Sweden has joined the Illumina Genome Network (IGN) to provide
researchers with broader access to Illumina’s whole genome sequencing
technology. SciLifeLab is the first IGN partner in Europe and will initiate a
national large-scale population sequencing program seeking to identify genetic
causes of human diseases.

“We now have the opportunity to offer an even larger capacity of high
throughput sequencing to researchers from all over Sweden. In the research
program we are about to launch, we aim to sequence more than 1,000 human
genomes using the Illumina systems,” said Joakim Lundeberg, Professor in Gene
Technology at KTH Royal Institute of Technology and Director of the National
Genomics Infrastructure at Science for Life Laboratory.

“We are very excited to welcome the SciLifeLab to our prestigious group of IGN
partners and to work with them on their groundbreaking national genome
sequencing project,” said Alex Dickinson, Senior Vice President Strategic
Initiatives for Illumina. “We look forward to working with SciLifeLab to speed
genetic discovery and establish a map of genetic variability in Sweden.”

IGN links researchers needing large-scale, whole human genome sequencing with
world class institutions that provide this service, and delivers unmatched
access to the highest quality of whole genome sequencing data. All IGN
partners are experienced and well-published using Illumina’s next-generation
sequencing technology, and have completed Illumina’s Certified Service
Provider (CSPro) certification. Each possesses ten or more Illumina
high-throughput sequencing systems, providing the scalability to handle large
sequencing projects with rapid completion times.

SciLifeLab joins twelve other IGN partners who provide a full range of WGS

  *British Columbia Cancer Agency in Vancouver, Canada
  *The Broad Institute in Cambridge, Massachusetts
  *Cold Spring Harbor Laboratory in Cold Spring Harbor, New York
  *HudsonAlpha Institute for Biotechnology in Huntsville, Alabama
  *Macrogen & Genomic Medicine Institute in Seoul, Korea
  *McGill University in Montreal, Canada
  *National Center for Genome Resources in Santa Fe, New Mexico
  *New York Genome Center in New York, New York
  *Northwest Genomics Center at University of Washington in Seattle,
  *Peking University in Beijing, China
  *Takara Bio, Shiga, Japan
  *Illumina’s FastTrack Services lab in San Diego, California

For more information about the Illumina Genome Network, please visit

About Illumina

Illumina ( is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

About SciLifeLab

Science for Life Laboratory (SciLifeLab) is a Swedish national center for
molecular biosciences with focus on health and environmental research. The
center combines frontline technical expertise with advanced knowledge of
translational medicine and molecular bioscience. SciLifeLab is a joint effort
between four Swedish universities (Karolinska Institutet, KTH Royal Institute
of Technology, Stockholm University and Uppsala University).

SciLifeLab was established in 2010 and appointed a national center in 2013 by
the Swedish government. More than 200 research groups are associated with
SciLifeLab, which is situated at two nodes in Stockholm and Uppsala.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this


Illumina, Inc.
Rebecca Chambers
Jennifer Temple
Press spacebar to pause and continue. Press esc to stop.